0VQ Stock Overview
Engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
PureTech Health plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£2.52 |
| 52 Week High | UK£2.82 |
| 52 Week Low | UK£1.60 |
| Beta | 0.98 |
| 11 Month Change | -3.82% |
| 3 Month Change | 0.40% |
| 1 Year Change | -4.36% |
| 33 Year Change | -37.00% |
| 5 Year Change | n/a |
| Change since IPO | -18.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0VQ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.8% | 0.04% | -3.5% |
| 1Y | -4.4% | -22.3% | 1.7% |
Return vs Industry: 0VQ exceeded the German Biotechs industry which returned -22.3% over the past year.
Return vs Market: 0VQ underperformed the German Market which returned 1.7% over the past year.
Price Volatility
| 0VQ volatility | |
|---|---|
| 0VQ Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 0VQ has not had significant price volatility in the past 3 months.
Volatility Over Time: 0VQ's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 90 | Bharatt Chowrira | www.puretechhealth.com |
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders.
PureTech Health plc Fundamentals Summary
| 0VQ fundamental statistics | |
|---|---|
| Market cap | €689.50m |
| Earnings (TTM) | -€61.22m |
| Revenue (TTM) | €3.10m |
222.2x
P/S Ratio-11.3x
P/E RatioIs 0VQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0VQ income statement (TTM) | |
|---|---|
| Revenue | US$3.33m |
| Cost of Revenue | US$96.24m |
| Gross Profit | -US$92.90m |
| Other Expenses | -US$27.21m |
| Earnings | -US$65.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | -2,789.94% |
| Net Profit Margin | -1,972.88% |
| Debt/Equity Ratio | 24.8% |
How did 0VQ perform over the long term?
See historical performance and comparison